PROCRITline.com - Site Map

Portal Home

For reimbursement information regarding other Centocor Ortho Biotech Inc. products, please click here.

PROCRITline.com Reimbursement Excellence

Site Map

To visit any of these areas on this website, just click on the highlighted text below. You'll go directly to that page.

PROCRITline.com Home Page

Billing & Reimbursement
Patient Resources
Full Prescribing Information including Boxed WARNINGS
Key Links
Helpful Resources
FAQ
Subscribe
Feedback
Medicare Prescription Drug Coverage News
Centocororthobiotech.com
PROCRIT.com

Billing & Reimbursement

Billing & Reimbursement Introduction
State Guidelines / CMS 1500

	Summary Part A
	Summary Part B
	CMS 1500 Examples
	Oncology 1 Initial Claim
	Oncology 2 Subsequent Claim
	Nephrology 1 Initial Claim
	Nephrology 2 Subsequent Claim
	Surgery 1 Initial Claim
	Surgery 2 Subsequent Claim
	AZT/HIV 1 Initial Claim
	AZT/HIV 2 Subsequent Claim
	State Medicare Payors

Medicare Guideline Archives
Medicare Guideline Update Table

Patient Resources

Patient Resources Introduction
Benefit Verification Form
Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF)

Prescribing Information

Prescribing Information Introduction
PROCRIT Full Prescribing Information including Boxed WARNINGS

Helpful Resources

Helpful Resources Introduction
PROCRIT Reimbursement - Overview
Quick Reference To ICD-9-CM Oncology Diagnosis Codes
Quick Reference To ICD-9-CM Nephrology Diagnosis Codes
Quick Reference To ICD-9-CM Surgery Diagnosis Codes
Quick Reference To ICD-9-CM Virology Diagnosis Codes
Oncology Toolkit

	Evaluation & Management Progress Note
	Chemotherapy Treatment Notes/Flow Sheet

PROCRIT Full Prescribing Information including Boxed WARNINGS
LEUSTATIN Full Prescribing Information including Boxed WARNINGS
Online Reimbursement & Health Care Resources

FAQ

Reimbursement Questions
Website / Technical Questions
Glossary

Footer Details

Home
Billing & Reimbursement
Patient Resources
Prescribing Information
Helpful Resources
FAQ
Glossary
Contact Us
Site Map
Legal Notice
Privacy Policy

Important Safety Information for PROCRIT^® (Epoetin alfa)

WARNINGS: INCREASED MORTALITY, SERIOUS CARDIOVASCULAR EVENTS, THROMBOEMBOLIC EVENTS, STROKE and INCREASED RISK OF TUMOR PROGRESSION OR RECURRENCE

Chronic Renal Failure:

In clinical studies, patients experienced greater risks for death, serious cardiovascular events, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target hemoglobin levels of 13 g/dL and above.

Individualize dosing to achieve and maintain hemoglobin levels within the range of 10 to 12 g/dL.

Cancer:

ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in some clinical studies in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers (see WARNINGS: Table 1).

To decrease these risks, as well as the risk of serious cardio- and thrombovascular events, use the lowest dose needed to avoid red blood cell transfusion.

Because of these risks, prescribers and hospitals must enroll in and comply with the ESA APPRISE Oncology Program to prescribe and/or dispense PROCRIT^® to patients with cancer. To enroll in the ESA APPRISE Oncology Program, visit www.esa-apprise.com or call 1-866-284-8089 for further assistance.

Use ESAs only for treatment of anemia due to concomitant myelosuppressive chemotherapy.

ESAs are not indicated for patients receiving myelosuppressive therapy when the anticipated outcome is cure.

Discontinue following the completion of a chemotherapy course.

Perisurgery: PROCRIT^® (Epoetin alfa) increased the rate of deep venous thromboses in patients not receiving prophylactic anticoagulation. Consider deep venous thrombosis prophylaxis.

(See WARNINGS: Increased Mortality, Serious Cardiovascular Events, Thromboembolic Events, and Stroke, WARNINGS: Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence, INDICATIONS AND USAGE, and DOSAGE AND ADMINISTRATION.)

Please see full Prescribing Information, including Boxed WARNINGS for PROCRIT^® (Epoetin alfa)

Medication Guide for PROCRIT^®
Please read the Medication Guide for PROCRIT^® and discuss with your doctor.

Patient Instructions for Use
Instructions if you or your caregiver has been trained to give PROCRIT^® injections at home.

Boxed WARNINGS: LEUSTATIN^® (cladribine) Injection

LEUSTATIN (cladribine) Injection should be administered under the supervision of a qualified physician experienced in the use of antineoplastic therapy. Suppression of bone marrow function should be anticipated. This is usually reversible and appears to be dose dependent. Serious neurological toxicity (including irreversible paraparesis and quadraparesis) has been reported in patients who received LEUSTATIN Injection by continuous infusion at high doses (4 to 9 times the recommended dose for Hairy Cell Leukemia). Neurologic toxicity appears to demonstrate a dose relationship; however, severe neurological toxicity has been reported rarely following treatment with standard cladribine dosing regimens.

Acute nephrotoxicity has been observed with high doses of LEUSTATIN (4 to 9 times the recommended dose for Hairy Cell Leukemia), especially when given concomitantly with other nephrotoxic agents/therapies.

Please see full Prescribing Information, including Boxed WARNINGS for LEUSTATIN^® (cladribine)